A5002562635- Multiple Myeloma Research and Treatments
- Mast cells and histamine
- Eosinophilic Disorders and Syndromes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Cancer Mechanisms and Therapy
- Peptidase Inhibition and Analysis
- Palliative Care and End-of-Life Issues
- Kruppel-like factors research
- Central Venous Catheters and Hemodialysis
- Urticaria and Related Conditions
- Hematological disorders and diagnostics
- Cancer Treatment and Pharmacology
- Drug-Induced Adverse Reactions
- Erythropoietin and Anemia Treatment
- Autoimmune Bullous Skin Diseases
- Lymphoma Diagnosis and Treatment
- Melanoma and MAPK Pathways
- Food Allergy and Anaphylaxis Research
- Cancer, Lipids, and Metabolism
- Neuroendocrine Tumor Research Advances
- Pathogenesis and Treatment of Hiccups
- Acute Kidney Injury Research
Guy's and St Thomas' NHS Foundation Trust
2021-2024
Guy's Hospital
2021-2024
St. Thomas Hospital
2024
St Thomas' Hospital
2022-2023
Royal Marsden NHS Foundation Trust
2015-2021
Royal Marsden Hospital
2014-2020
Institute of Cancer Research
2016-2020
Orpington Hospital
2018
Google (United States)
2016
St Helier Hospital
2015
Abstract Advanced systemic mastocytosis (AdvSM) is a rare myeloid neoplasm associated with poor overall survival (OS). This study (NCT04695431) compared clinical outcomes between patients AdvSM treated avapritinib in the Phase 1 EXPLORER (NCT0256198) and 2 PATHFINDER (NCT03580655) trials ( N = 176) best available therapy (BAT; 141). A multi-center, observational, retrospective chart review was conducted at six sites (four European, two American) to collect data from who received BAT; these...
A central feature of myeloproliferative neoplasms (MPN) is an increased risk cardiovascular thrombotic complications, and this the primary determinant for introduction cytoreductive therapy.1 The landmark ECLAP study in polycythemia vera (PV) patients, showed mortality accounted 45% all deaths, with a thrombosis incidence rate 1.7/100 person/year cumulative 4.5% over median follow-up 2.8 years.2 Natural language processing (NLP) branch machine learning involving computational interpretation...
The introduction of central venous catheters has advanced medical care, particularly in hemato-oncology. However these can be associated with an increased thrombotic risk. Previous studies have compared the rate events between peripherally- inserted (PICCs) and long term skin tunneled (LTSTCs) noting fewer complications latter, though this rarely translated into clinical practice. objectives our study was to compare cumulative incidence peripherally-inserted catheters.We performed a...
2506 Background: RO5126766 is a potent RAF and MEK inhibitor with activity in xenografts models of RAS RAF-mutated cancers. We present data from the RAS/RAF-mutated advanced solid tumor cohort initial results for multiple myeloma (MM) cohort. Methods: Patients KRAS, NRAS or BRAF-mutant tumours were treated RO5127566 using novel schedule:4mg twice weekly 4-week cycles. For MM patients, it was given 3 weeks out 4 co-administration dexamethasone authorised. Response assessment completed RECIST...
Despite widespread use of Pegylated forms Inteferon in the management Myeloproliferative Neoplasms (MPN), most clinicians have experience predominantly with peginterferon alfa-2a (Pegasys). Third generation pegylated IFNα, ropeginterferon alfa-2b (ropegIFN; Besremi), was recommended by European Medicine Authority (EMA) for treatment Polycythaemia Vera (PV) following a Phase III trial (PROUD-PV / CONTINUATION-PV). FDA approval PV, regardless history, subsequently granted November 2021. We...
Multiple myeloma (MM) remains incurable despite recent therapeutic advances. RAS mutations are frequently associated with relapsed/refractory disease. Efforts to target the mitogen-activated protein kinase (MAPK) pathway MEK inhibitor, trametinib (Tra) have been limited by toxicities and development of resistance. Dexamethasone (Dex) is a corticosteroid commonly used in clinical practice, enhance efficacy anti-myeloma therapy. Therefore, we hypothesised that combination Tra Dex would yield...
The treatment of relapsed multiple myeloma (MM) is challenging due to increasing disease refractoriness, declining patient performance status and co-morbidity.1 combination panobinostat, bortezomib dexamethasone (PAN-Vd) approved for the patients with MM based on PANORAMA1 trial which compared PAN-Vd placebo-Vd in who were not previously refractory bortezomib.2, 3 Subgroup analysis showed that benefit from was greatest had received ≥2 prior regimens including an immunomodulatory drug (IMiD)...
Current therapies for multiple myeloma, which include corticosteroids, increase risk of avascular necrosis. The aim this study was to assess incidental detection femoral head necrosis on routine whole body MRI including diffusion weighted MRI.All studies, performed patients with known myeloma between 1 January 2010 May 2017 were assessed features necrosis.650 MR scans analysed. 15 (6.6%) had typical necrosis: 2/15 (13.3%) collapse, 4/15 (26.7%) bilateral and 9/15 (60%) asymptomatic.This is...
Mastocytosis is a group of heterogeneous conditions characterized by clonal proliferation abnormal mast cells in the skin and/or other organs. There are 3 major subforms: cutaneous mastocytosis (CM), which there but no systemic involvement; (SM), presence extracutaneous organs, with or without and cell sarcoma. SM can be further subclassified into 5 types, involvement: indolent (ISM), smoldering, aggressive forms; an associated hematological neoplasm (SM-AHN); leukemia.1 The clinical...
Assessing blood clot risk in venous catheter selection for patients with haematological cancers Venous catheters enable to receive vital chemotherapy. However, there is a of thrombosis. Consultant Haematologist Priya Sriskandarajah analysed group study the implications selection. Over years, have been major developments cancer care, including novel chemotherapy regimens as well stem cell transplantation. To support these advancements and efficient treatment administration, (i.e. ‘lines’) are...